Charles C. Peyton

Urology

2000 6th Ave S
Birmingham, AL 35233

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Survival outcomes after cytoreductive nephrectomy with tumor thrombectomy: results from the Intercontinental Collaboration on Renal Cell Carcinoma.

Survival outcomes after cytoreductive nephrectomy with tumor thrombectomy: results from the Intercontinental Collaboration on Renal Cell Carcinoma.

Journal: Minerva urology and nephrology

Published: May 20, 2026

Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: May 15, 2026

Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size-dependent survival in pT3N0M0 clear cell renal cell carcinoma.

Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size-dependent survival in pT3N0M0 clear cell renal cell carcinoma.

Journal: Urologic oncology

Published: March 02, 2026

Less Is More? How Much Bacillus Calmette-Guérin (BCG) Is Enough for BCG-naïve High-risk Non-muscle invasive Bladder Cancer?

Less Is More? How Much Bacillus Calmette-Guérin (BCG) Is Enough for BCG-naïve High-risk Non-muscle invasive Bladder Cancer?

Journal: European urology

Published: January 21, 2026

Impact of intraoperative intravenous heparin bolus on clinical outcomes during radical nephrectomy and IVC tumor thrombectomy in renal cell carcinoma with level I-IV IVC thrombus: A multi-institutional study.

Impact of intraoperative intravenous heparin bolus on clinical outcomes during radical nephrectomy and IVC tumor thrombectomy in renal cell carcinoma with level I-IV IVC thrombus: A multi-institutional study.

Journal: Urologic oncology

Published: December 30, 2025

Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer.

Psychometric Validation of the QLQ-NMIBC24 in Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer.

Journal: Research and reports in urology

Published: December 24, 2025

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer.

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 15, 2025

Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results.

Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 03, 2025

Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical Trials.

Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical Trials.

Journal: Urology practice

Published: November 11, 2025

Contemporary Role for Blue Light Cystoscopy Across the Bladder Cancer Disease Spectrum.

Contemporary Role for Blue Light Cystoscopy Across the Bladder Cancer Disease Spectrum.

Journal: Current urology reports

Published: October 10, 2025

Comparing Cytoreductive Nephrectomy with Tumor Thrombectomy Between Open, Laparoscopic, and Robotic Approaches.

Comparing Cytoreductive Nephrectomy with Tumor Thrombectomy Between Open, Laparoscopic, and Robotic Approaches.

Journal: Cancers

Published: October 08, 2025

Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete Metastasectomy.

Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete Metastasectomy.

Journal: The Journal of urology

Published: August 05, 2025

Showing 1-12 of 70

Last Updated: 09/26/2026